NHS National Pharmaceuticals Transition 2021_2 - Pemetrexed LSNE
Offer reference number: CM/PHG/21/5639/00 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months) Potential periods of call-offs under the framework agreement: 24/06/2021 to 31/01/2023 (19 months) LSNE region.
Buyer
NHS England
Value
£1,520
Published
14 Jul 2021
Closes
26 May 2021
Procurement details
Source
Contracts Finder
Region
London
Procurement method
Open
Category
Goods
Contract starts
23 Jun 2021
Contract ends
31 Jan 2023
CPV classifications
33600000
Pharmaceutical products
Lots
Lot default NHS National Pharmaceuticals Transition 2021_2 - Pemetrexed LSNE
£1,520
Offer reference number: CM/PHG/21/5639/00 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months) Potential periods of call-offs under the framework agreement: 24/06/2021 to 31/01/2023 (19 months) LSN...
Delivery: United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
14 Jul 2021
Awarded contract notice on Contracts Finder
Award notice · Web page
Parties appointed to the Framework Agreement & SME status - Transition 2021_2 - Pemetrexed LSNE
Not provided
Parties appointed to the Framework Agreement & SME status - Transition 2021_2 - Pemetrexed LSNE
Link
Link to Find a Tender Award notice for Transition 2021_2 - Pemetrexed Solution for Infusion LSNE
Not provided
Link to Find a Tender Award notice for Transition 2021_2 - Pemetrexed Solution for Infusion LSNE
Link
Transparency Award Schedule CM_PHG_21_5639_00
Not provided
Transparency Award Schedule CM_PHG_21_5639_00
Link
Document No. 03 - Framework Agreement and Terms and Conditions
Not provided
Document No. 03 - Framework Agreement and Terms and Conditions
Link
Contains public sector information licensed under the Open Government Licence v3.0.